Skip to main content
. Author manuscript; available in PMC: 2007 Oct 1.
Published in final edited form as: Neurobiol Aging. 2005 Aug 30;27(10):1435–1439. doi: 10.1016/j.neurobiolaging.2005.07.015

Figure 1.

Figure 1

Kaplan-Maier survival analysis for age-at-onset (AAO). The AAO is plotted against the proportion unaffected by AD. (A) = Comparison of no copy of APOE*4 allele (2/2, 2/3, 3/3 genotypes), one copy of APOE*4 allele (2/4, 3/4 genotype) and two copies of APOE*4 allele (4/4 genotype) on AAO. At age 70, 72.1% subjects with no APOE*4, 54.8% with one APOE*4 and 31.7% with two APOE*4 are unaffected by AD (log rank 75.2, df = 5, p<0.0001). (B) = Comparison of ACT/AA and AT + TT genotypes on AAO. At age 70, 61.2% subjects with AT + TT genotype and 53.8% with AA genotype are unaffected by AD (log rank 3.4, df = 1, p=0.066). (C) = Comparison of ACT genotype on AAO among APOE*4 carriers. At age 70, 54% subjects with ACT/AT + TT genotype and 42.4% with ACT/AA genotype are unaffected by AD (log rank = 5.8, df = 1, p=0.016). (D) = Comparison of ACT genotype on AAO among non-APOE*4 carriers (log rank 0.3, df = 1, p=0.61).